Table 1:

Adoptive T-cell Therapies for Glioblastoma in Development

Type	Mechanism	Sponsor Institution: Identifier
Lymphokine-activated killer cells	Unknown, likely MHC-independent	Hoag Memorial Hospital Presbyterian: NCT00331526
Allogeneic donor lymphocyte infusion	Graft versus tumor HLA-mismatch, may include viral antigens (CMV)	City of Hope Medical Center: NCT01082926 Jonsson Comprehensive Cancer Center: NCT01144247 Milton S. Hershey Medical Center: NCT00990496 University of Colorado: NCT00002572
Autologous lymphocytes	MHC-restricted TCR recognition, may include viral antigens (CMV)	Baylor College of Medicine: NCT01205334 CytoVac A/S: NCT01588769 Duke University Medical Center: NCT00693095 Green Cross Cell Corporation: NCT00807027 Huashan Hospital: NCT03347097 M.D. Anderson Cancer Center: NCT02661282 TVAX Biomedical: NCT01290692, NCT01081223
Tumor infiltrating lymphocytes	MHC-restricted TCR recognition	National Cancer Institute: NCT01174121
Transgenic T-cell receptor T cells	MHC-restricted TCR recognition	National Cancer Institute: NCT03412877
Antibody-armed T cells	MHC-independent antigen recognition	Barbara Ann Karmanos Cancer Institute: NCT02521090 University of Virginia: NCT03344250
Chimeric antigen receptor T cells	MHC-independent antigen recognition coupled with intracellular signaling domains	Baylor College of Medicine: NCT01109095, NCT02442297 Beijing Sanbo Brain Hospital: NCT02844062, NCT02937844 City of Hope Medical Center: NCT00730613, NCT03389230, NCT02208362 Duke University Medical Center: NCT02664363, NCT03283631 Fuda Cancer Hospital: NCT02575261 National Cancer Institute: NCT01454596 RenJi Hospital: NCT02331693 Shenzhen Geno-Immune Medical Institute: NCT03170141 University of Pennsylvania: NCT02209376

Abbreviations: MHC = major histocompatibility complex; HLA = human leukocyte antigen; CMV = cytomegalovirus, TCR = T-cell receptor